$ARWR News
Last published 13h ago
- 13h agoARWRARROWHEAD PHARMACEUTICALS, INC. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 13h agoARWRArrowhead Pharmaceuticals Reports 2026 Fiscal Year-End ResultsBusiness WirePASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2026 fiscal year ended September 30, 2026. The Company is hosting a conference call today, November 12, 2026, at 4:30 p.m. ET to discuss the results. “Arrowhead has fundamentally changed over the past 12 months. Where there was once a company that relied solely on g ...
- 3d agoARWRArrowhead Pharmaceuticals to Participate in Upcoming Investor ConferencesBusiness WirePASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events:2026 Jefferies Global Healthcare Conference in London – November 16-19, 2026Type: Fireside Chat PresentationDate/Time: November 18, 2026, 11:00 am GMTCiti’s 2026 Global Healthcare Conference – November 30 - Decembe ...
- 5d agoARWRArrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis RatesBusiness WirePASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented results on two of the RNA interference (RNAi) based therapies in its cardiometabolic pipeline at the American Heart Association (AHA) Scientific Sessions 2026 in Chicago. The presentations included multiple studies of plozasiran in patients with familial chylomicronemia syndrome (FCS) and severe hyper ...
- 2w agoARWRAdults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce TriglyceridesBusiness WireThe UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Marketing Authorisation for REDEMPLO® (plozasiran) as an adjunct to diet to reduce triglyceride levels in adult patients with Familial
- 4w agoARWRArrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy VolunteersBusiness WireArrowhead’s TRiM™ platform achieves clinical validation for delivery of siRNA that crosses the blood-brain barrier after subcutaneous injection ARO-MAPT demonstrates mean cerebrospinal fluid total tau reduction of
- 1mo agoARWRArrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe HypertriglyceridemiaBusiness Wire- FDA STAR pilot program aims to shorten the time from complete supplement submission to the action date to allow earlier patient access to therapies that address an unmet medical need Arrowhead Pharmaceuticals, Inc.
- 1mo agoARWRArrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other TauopathiesBusiness Wire– ARO-MAPT utilizes the Targeted RNAi Molecule (TRiM™) platform designed for subcutaneous administration and systemic delivery to the CNS by crossing the blood-brain barrier – Arrowhead Pharmaceuticals, Inc.
- 1mo agoARWRMorgan Stanley 24th Annual Global Healthcare Conference - ARROWHEAD PHARMACEUTICALS INCEarnings Call TranscriptsAll right. Hello, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I'm Mike Goltz, one of the biotech analysts here, and it's my pleasure to introduce the team from Arrowhead Pharma
- 1mo agoARWRArrowhead Pharmaceuticals - Morgan Stanley 24th Annual Global Healthcare Conference - ARROWHEAD PHARMACEUTICALS INCEarnings Call TranscriptsAll right. Hello, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I'm Mike Goltz, one of the biotech analysts here, and it's my pleasure to introduce the team from Arrowhead Pharma
- 1mo agoARWRArrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed HyperlipidemiaBusiness Wire- ARO-DIMER-PA achieved deep and durable silencing of two genes with a single RNAi molecule - Mean maximal single dose reductions in serum PCSK9 of 72% and APOC3 of 88% - Clinical validation further demonstrates
- 2mo agoARWRArrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor ConferencesBusiness WireArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it is scheduled to participate in the following upcoming investor events: 2026 Cantor Global Healthcare Conference – September 9-11, 2026 Type:
- 2mo agoARWRArrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe HypertriglyceridemiaBusiness Wire- Plozasiran reduced triglycerides (TG) by 79% and 81% versus placebo in SHASTA-3 and SHASTA-4 across the broad sHTG population - - More than 90% of plozasiran-treated patients achieved triglycerides below thresholds
- 2mo agoARWRArrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology CongressBusiness Wire- Detailed results from the Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia will be presented as a HOT LINE Late-Breaking Science Session on August 30, 2026 - -
- 2mo agoARWRPeople Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce TriglyceridesBusiness WireREDEMPLO® (plozasiran) is listed in the Lauer-Taxe® database as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronaemia syndrome (FCS), diagnosed either based on clinical
- 3mo agoARWRArrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter ResultsBusiness Wire- Conference Call and Webcast Today, August 4, 2026, at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced financial results for its fiscal 2026 third quarter ended June 30, 2026. The Company
- 3mo agoARWRArrowhead Pharmaceuticals Acquires FDA Priority Review VoucherBusiness Wire- Voucher to be used to accelerate review of a planned sNDA for plozasiran in severe hypertriglyceridemia Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it has signed an agreement with an
- 3mo agoARWRArrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)Business WireArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that as an inducement to entering into employment with the Company, on July 16, 2026, the Company’s Board of Directors approved "inducement" grants
- 3mo agoARWRArrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial HypercholesterolemiaBusiness Wire- Study completion anticipated in mid-2027 Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it has completed enrollment in the global Phase 3 YOSEMITE clinical trial of zodasiran, the company’s
- 3mo agoARWRArrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe HypertriglyceridemiaBusiness WireDeep, durable, and consistent median triglyceride reductions of 79% and 81% from baseline in SHASTA-3 and SHASTA-4, respectively Statistically significant reduction in acute pancreatitis events versus placebo
- 3mo agoARWRArrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter ResultsBusiness WireArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on August 4, 2026, at 4:30 p.m. ET to discuss its financial results for the fiscal 2026 third quarter ended
- 4mo agoARWRArrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)Business WireREDEMPLO is the first and only authorised treatment for adults with FCS that does not require genetic confirmation of the conditionPeople living with FCS have extremely high triglyceride levels and a substantially
- 4mo agoARWRArrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D WebinarsBusiness WireArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced its plan to host a 2026 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the
- 5mo agoARWRGoldman Sachs 47th Annual Global Healthcare ConferenceARROWHEAD PHARMACEUTICALS INCEarnings Call TranscriptsGood morning, and thank you for joining us on day three of the 47th annual Goldman Sachs Global Healthcare Conference. I'm Paul Choi, and I cover this mid-cap biotech sector here at the firm. It's our pleasure to have Ar
- 5mo agoARWRJEFFERIES GLOBAL HEALTHCARE CONFERENCE IN NEW YORK - ARROWHEAD PHARMACEUTICALS INCEarnings Call TranscriptsMy name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. I'm happy to introduce and welcome James Hamilton, the CMO, and Dan Appel, CFO of Arrowhead Pharmaceuticals. This is a fireside chat. Thanks so
- 5mo agoARWRArrowhead Pharmaceuticals to Participate in Upcoming June 2026 EventsBusiness WireArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it is scheduled to participate in the following upcoming events: 2026 Jefferies Global Healthcare Conference – June 2-4, 2026 Type: Fireside Chat
- 5mo agoARWRArrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026Business Wire- Targeting Activin E may represent a novel therapeutic strategy for metabolic dysfunction-associated steatohepatitis (MASH) and obesity‑related metabolic dysfunction - ARO-INHBE produced meaningful reductions in
- 5mo agoARWRArrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) CongressBusiness Wire- New data support potential use of plozasiran without dose adjustment in patients with moderate-to-severe renal or moderate hepatic impairment - Case report suggests that preconception exposure to plozasiran may be
- 6mo agoARWR2026 GLOBAL HEALTHCARE CONFERENCEARROWHEAD PHARMACEUTICALS INCEarnings Call TranscriptsAll right, everybody. We're going to get going here with our next company presenter at the B of A Annual Healthcare Conference. My name is Jason Gerberry. I cover pharma and biotech here, and I am joined by CEO Chris Anz
- 6mo agoBBIOBMYARWRAMGNWall Street's Cardiac Bet: Where Diagnostics Meet the MoneyPR NewswireCardiovascular disease is about to become the most expensive problem in American medicine. The American Heart Association fired a warning shot in...
- 6mo agoARWRArrowhead Pharmaceuticals Fiscal 2026 Second Quarter ResultsARROWHEAD PHARMACEUTICALS INCEarnings Call TranscriptsLadies and gentlemen, welcome to the Arrowhead Pharmaceuticals conference call. Throughout today's presentation, all participants will be in listen-only mode. After the presentation, there will be an opportunity to ask q
- 6mo agoARWRArrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter ResultsBusiness Wire- Conference Call and Webcast Today, May 7, 2026, at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced financial results for its fiscal 2026 second quarter ended March 31, 2026. The Company is
- 6mo agoARWRMDGLArrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal PharmaceuticalsBusiness Wire- Precision approach targets patients who have a mutation in the PNPLA3 gene, which is highly prevalent among Hispanic patients with MASH - Phase 1 data published in The New England Journal of Medicine demonstrated a
- 6mo agoARWRArrowhead Pharmaceuticals to Participate in Upcoming May 2026 EventsBusiness WireArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it is scheduled to participate in the following upcoming events: BofA Securities 2026 Healthcare Conference – May 12-14, 2026 Type: Investor Group
- 6mo agoARWRArrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)Business Wire– REDEMPLO is the first and only medicine approved for use in the treatment of FCS in Australia, and is authorized for both genetically confirmed and clinically diagnosed adult patients with FCS – People living with
- 6mo agoARWRArrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in EuropeBusiness Wire– If confirmed by the European Commission, REDEMPLO would be the first and only siRNA medicine authorized in the EU for both genetically confirmed and clinically diagnosed adult patients with FCS – People living with
- 6mo agoARWRArrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter ResultsBusiness WireArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on May 7, 2026, at 4:30 p.m. ET to discuss its financial results for the fiscal 2026 second quarter ended
- 7mo agoARWRArrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology's 75th Annual Scientific Session and ExpoBusiness Wire– Patients with severe hypertriglyceridemia (sHTG) achieved an 83% median reduction in triglycerides (TG), with 96% of patients achieving TG levels below 500 mg/dL, a threshold associated with increased risk of acute
- 7mo agoVRTXCRSPALTARWRAnti-Aging Protein Research Takes a Step Forward with Cell CloningPR NewswireEquity-Insider.com — A protein called α-Klotho circulating in the bloodstream protects the brain, heart, kidneys, and the immune system....
- 8mo agoARWRArrowhead Pharmaceuticals to Participate in Upcoming March 2026 EventsBusiness WireArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it is scheduled to participate in the following upcoming events: TD Cowen 46th Annual Health Care Conference – March 2-4, 2026 Type: Fireside Chat
- 8mo agoARWRJNJMGTXOTLC+1Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&AGlobeNewswireAUSTIN, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage
- 9mo agoARWRArrowhead Pharmaceuticals Fiscal 2026 First Quarter ResultsARROWHEAD PHARMACEUTICALS INCEarnings Call TranscriptsLadies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call. Throughout today's recorded presentation, all participants will be in a listen-only mode. After the presentation, there will be an opportuni
- 9mo agoARWRArrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter ResultsBusiness Wire- Conference Call and Webcast Today, February 5, 2026, at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced financial results for its fiscal 2026 first quarter ended December 31, 2025. The
- 9mo agoMNKDALTLCTXARWRLongevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell RestorationPR NewswireUSA News Group News Commentary – Global capital is officially rotating into "Longevity Infrastructure" which is now valued at a massive $27 trillion...
- 9mo agoARWRArrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter ResultsBusiness WireArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on February 5, 2026, at 4:30 p.m. ET to discuss its financial results for the fiscal 2026 first quarter ended
- 10mo agoARWRArrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body CompositionBusiness Wire- ARO-INHBE in combination with tirzepatide achieved -9.4% weight loss at week 16 in obese patients with type 2 diabetes mellitus, demonstrating an approximately two-fold improvement versus -4.8% on tirzepatide
- 10mo agoARWRArrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)Business Wire– REDEMPLO is the first and only Health Canada-approved siRNA medicine to be studied in patients with genetically confirmed and clinically diagnosed FCS – People living with FCS have extremely high triglyceride levels
- 10mo agoARWRArrowhead Pharmaceuticals to Participate in Upcoming January 2026 EventsBusiness WireArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it is scheduled to participate in the following upcoming events: Obesity KOL Webinar – ARO-INHBE and ARO-ALK7 Interim Clinical Data – January 6,
- 11mo agoARWRArrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)Business WireArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that as an inducement to entering into employment with the Company, on December 12, 2025, the Company's Board of Directors approved "inducement" grants to 78
- 11mo agoARWRArrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other TauopathiesBusiness Wire- ARO-MAPT utilizes the Targeted RNAi Molecule (TRiM™) platform designed for subcutaneous administration and systemic delivery to the CNS by crossing the blood-brain-barrier - Study initiation further highlights